Phenotype or virtual phenotype for choosing antiretroviral therapy after failure: A prospective, randomized study

Antiviral Therapy

Volumn 8, Issue 6, 2003, Pages 577-584

  Perez Elias, María Jesús ^a   Garcia Arata, Isabel ^a   Muñoz, Vicente ^a   Santos, Ignacio ^b   Sanz, José ^c   Abraira, Víctor ^a   Arribas, José R ^d   González, Juan ^d   Moreno, Ana ^a   Dronda, Fernando ^a   Antela, Antonio ^a   Pumares, María ^a   Martí Belda, Paloma ^a   Casado, Jose L ^a   Geijo, Paloma ^e   Moreno, Santiago ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LOPINAVIR; RITONAVIR; VIRUS RNA;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; DOUBLE-BLIND METHOD; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PHENOTYPE; PROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 9144233519     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S & Volberding PA. Antiretroviral treatment for adult HIV infection in 2002: Updated recommendations of the International AIDS Society-USA Panel. Journal of the American Medical Association 2002; 2:222-235.
2. Casado JL, Perez-Elias MJ, Antela A, Sabido R, Marti-Belda P, Dronda F, Blazquez J & Quereda C. Predictors of long-term response to protease inhibitor therapy in HIV-infected patients. AIDS 1998; 12:F131-F135.
3. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, Vernazza P, Sudre P, Flepp M, Furrer H, Francioli P & Weber R. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999; 353:863-868.
4. Lucas GH, Chaisson RE & Moore RD. Highly active anti-retroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Annals of Internal Medicine 1999; 131:81-87.
5. Hirsch MS, Brun-Vezinet F, D'Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR, Loveday C, Mellors JW, Clotet B, Conway B, Demeter LM, Vella S, Jacobsen DM & Richman DD. Antiretroviral drug resistance testing in adult HIV-1 infection. Journal of the American Medical Association 2000; 283:2417-2426.
6. Hughes M. Analysis and design issues for studies using censored biomarker measurements with an example of viral load measurements in HIV clinical trials. Statistics in Medicine 2000; 19:3171-3191.
7. Deeks SG, Hellmann NS, Grant RM, Parkin NT, Petropoulos CJ, Becker M, Symonds W, Chesney M & Volberding PA. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. Journal of Infectious Diseases 1999; 179:1375-1381.
8. Lorenzi P, Opravil M, Hirschel B, Chave JP, Furrer HJ, Sax H, Perneger TV, Perrin L, Kaiser L & Yerly S. Impact of drug resistance mutations on virologic response to salvage therapy. AIDS 1999; 13:F17-F21.
9. Perez-Elias MJ, Lanier R, Munoz V, Garcia-Arata I, Casado JL, Marti-Belda P, Moreno A, Dronda F, Antela A, Marco S & Moreno S. Phenotypic testing predicts virological response in successive protease inhibitor-based regimens. AIDS 2000; 14:F95-F101.
10. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, Montagne N, Boucher CA, Schapiro JM & Dellamonica P. Drug-resistance genotyping in HIV therapy: The VIRADAPT randomized controlled trial. Lancet 1999; 353:2195-2199.
11. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, Mannheimer SB, Thompson MA, Abrams DI, Brizz BJ, Ioannidis JP & Merigan TC. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS 2000; 14:F83-F93.
12. The Euroguide-lines Group. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as a part of the treatment management: recommendations for the European setting. AIDS 2001; 15:309-320.
13. M Dybul, AS Fauci, JG Bartlett, JE Kaplan & AK Pau. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Annals of Internal Medicine 2002; 137:381-433.
14. Larder BA, Kemp SD & Hertogs K. Quantitative prediction of HIV-1 phenotypic drug resistance from genotypes: the virtual phenotype (VirtualPhenotype). Antiviral Therapy 2000; 5:49. Abstract 63.
15. Graham N, Peeters M, Verbiest W, Harrigan R & Larder B. The Virtual Phenotype is an independent predictor of clinical response. 8th Conference on Retroviruses & Opportunistic Infections; February 4-8, 2001; Chicago, III., USA. Abstract 524.
16. Mazzota F, Lo Caputo S, Scudeller L, Tortic C & Tinelli C. Real versus to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-fenotipo di resistenza (Genepherex) trial. Journal of Acquired Immune Deficiency Syndromes 2003; 32:268-280.
17. Wegener S, Wallace L, Tasker S, Aronson N, Blazes D, Tamminga C, Fraser S, Stephan K, Jagodzinski L, Vahey M, Tracy L, Rinehart A, Graham N, Hertogs K & Birx D. Long term efficacy of resistance testing: results of the CERT trial. Antiviral Therapy 2002; 7:S129.
18. Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, Gonzalez J, Domingo P, Boucher C, Rey-Joly C & Clotet B. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS 2002; 16:209-218.
19. Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, Matheron S, Lamotte C, Guiramand S, Costagliola D, Brun-Vezinet F, Clavel F & Girard PM. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS 2002; 16:727-736.
20. Cohen CJ, Hunt S, Sension M, Farthing C, Conant M, Jacobson S, Nadler J, Verbiest W, Hertogs K, Ames M, Rinehart AR & Graham NM. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 2002; 16:579-588.
21. Haubrich R, Keiser P, Kemper C, Witt M, Leedom J, Forthol D & Hellman N. CCTG 575: a randomized, prospective study of phenotype testing (Pheno) versus standard of care (SOC) for patients failing antiretroviral therapy (ARV). 1st IAS Conference on HIV Pathogenesis & Treatment. Buenos Aires, Argentina, July 8-11, 2001. Abstract 127.
22. Zolopa AR, Lazzeroni LC, Rinehart A & Kuritzkes D for the Guess investigators. Accuracy, precision and consistency of expert HIV-1 genotype interpretation: an international comparison (the GUESS study). Antiviral Therapy 2002; 7:S97.
23. Ravela J, Betts BJ, Brun-Vezinet F, Vandamme AM, Descamps D, van Laethem K, Smith K, Schapiro JM, Winslow DL, Reid C & Shafer RW. HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms. Journal of Acquired Immune Deficiency Syndromes 2003 33:8-14.